It is now becoming clear that SP/NK‐1R signaling is involved in cancer pathogenesis and promotes proliferation, angiogenesis, and metastasis of cancer cells, which has been well summarized in several reviews.[4, 22] Therefore, NK‐1R antagonists can be used as a novel approach for cancer treatment. The gene discussed is TACR1; the disease is cancer.